Bradley Eilerman, MD
Endocrinology, Diabetes & Metabolism · Florence, KYNPI 1841389822
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,032,546 of the $1,279,959 with a category attached, or 80.7%. 60 manufacturers reported payments, led by Corcept Therapeutics at 30.7% of the total. Among endocrinology, diabetes & metabolism clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,752 payments — averaging $465.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$393K
- Novo Nordisk$320K
- Lilly USA, LLC$288K
- Dexcom, Inc.$65K
- AstraZeneca$46K
- Bayer$37K
- plus $131K from 54 others
Across 108 payments — averaging $5468.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$284K
- Boehringer Ingelheim International GmbH$198K
- Novo Nordisk AS$36K
- Eli Lilly$34K
- Ascendis Pharma Endocrinology Inc$24K
- Corcept Therapeutics$7K
- plus $7K from 1 others
What the payments were for
- Consulting fees$81,6466%
- Speaking & faculty fees$1,032,54681%
- Travel & lodging$117,6219%
- Food & beverage$46,3654%
- Education$1,7300%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$387,747
- ZEPBOUND$154,629
- Saxenda$123,683
- MOUNJARO$101,246
- Wegovy$78,195
- Ozempic$49,404
- JARDIANCE$46,956
- FARXIGA$44,424
- RYBELSUS$40,322
- Kerendia$36,110
- DEXCOM G7 GSS (161)$35,373
- SOLIQUA 100/33$18,727
- DEXCOM G6 TRANSMITTER$17,281
- DEXCOM STELO GLUCOSE BIOSENSOR$10,599
- Synthroid$9,164
- JATENZO$7,089
- STEGLATRO$7,049
- INVOKANA$7,000
- ISTURISA$6,409
- TOUJEO$6,236
How this compares
$1,279,959 in reported general payments places this provider in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 58 | $1,371,206 |
| OzempicSemaglutide | 366 | $686,095 |
| MounjaroTirzepatide | 402 | $563,911 |
| JardianceEmpagliflozin | 378 | $467,489 |
| Mifepristone | 15 | $329,003 |
| TrulicityDulaglutide | 81 | $146,010 |
| FarxigaDapagliflozin Propanediol | 118 | $143,882 |
| Tresiba Flextouch U-200Insulin Degludec | 63 | $95,813 |
| ForteoTeriparatide | 19 | $79,466 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $77,142 |
| RybelsusSemaglutide | 41 | $69,030 |
| Tresiba Flextouch U-100Insulin Degludec | 81 | $49,988 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 29 | $45,775 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $44,439 |
| Repatha SureclickEvolocumab | 48 | $40,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $393,403 | $1,371,20658 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Wegovy, Novolog | $320,009 | $846,062487 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $287,651 | $802,650538 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $32,752 | $529,159438 claims |
| AstraZenecaFarxiga | $46,207 | $143,882118 claims |
| MerckJanuvia, Janumet Xr | $7,436 | $43,43944 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $26,016 | $23,44513 claims |
| Johnson & JohnsonInvokana | $7,336 | $20,13013 claims |
| AbbVieSynthroid | $9,637 | $15,991224 claims |
| Astellas Pharma US IncVeozah | $125 | $11,76112 claims |
| BayerKerendia | $36,772 | $11,75514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Florence
- Heather CornFlorence$13K
- Ann BeersFlorence$6K
- Malik Waseem AhmadFlorence$2K
- Sanjana AwastyFlorence$2K
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Yancey HolmesCovington$148K
- Moussa AlhajAshland$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.